BBIO ▲ +1.3% - BridgeBio Pharma, Inc. $BBIO - BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia 06-OCT-2026 07:30 AM ET